JFD00244

JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2[1][2].

Product Specifications

CAS Number

[96969-83-4]

UNSPSC

12352005

Hazard Statement

H410

Target

SARS-CoV; Sirtuin

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jfd00244.html

Purity

99.40

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C2=C(C=CC=C2)C(C3=C(NCCC4=CC=C(O)C=C4)C=CC(NCCC5=CC=C(O)C=C5)=C13)=O

Molecular Formula

C30H26N2O4

Molecular Weight

478.54

Precautions

H410

References & Citations

[1]Ciarlo C, A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development. Elife. 2017 Aug 23;6. pii: e29145.|[2]Shankar U, et al. Potential Drugs Targeting Nsp16 Protein May Corroborates a Promising Approach to Combat SARSCoV-2 Virus. ChemRxiv. Cambridge: Cambridge Open Engage; 2020; This content is a preprint and has not been peer-reviewed. |[3]Kim Dae Jung, et al. Pharmaceutical composition for preventing and treating prostate cancer: World Intellectual Property Organization, WO2014065537[P]. 2014-05-01.